San Diego, January 7, 2026
Candid Therapeutics, a San Diego-based biotech firm, is set to present at the upcoming J.P. Morgan Healthcare Conference. CEO Dr. Ken Song will discuss the company’s advancements in T-cell engagers aimed at treating autoimmune and inflammatory diseases. The conference, a prominent platform for healthcare innovations, runs from January 12 to 15, highlighting Candid’s role in transforming treatment approaches and showcasing San Diego’s thriving biotech scene.
San Diego Company Candid Therapeutics to Present at J.P. Morgan Healthcare Conference
CEO Dr. Ken Song to Share Insights on T-Cell Engagers
San Diego, CA – Candid Therapeutics, Inc., an innovative biotechnology firm based out of San Diego, is set to present at the 44th Annual J.P. Morgan Healthcare Conference. Scheduled for January 14, 2026, at 7:30 a.m. PT, Dr. Ken Song, the company’s Chairman, President, and CEO, will discuss Candid’s ongoing clinical advancements and its novel T-cell engager (TCE) portfolio aimed at treating autoimmune and inflammatory diseases.
This prestigious annual event, which runs from January 12 to 15, 2026, in San Francisco, California, serves as a critical platform where healthcare firms, emerging companies, and investors convene to share developments. Candid Therapeutics, established in 2024 and focused on groundbreaking therapies, will be among the key players presenting to a global audience.
The Importance of Innovation in Biotechnology
With a mission centered on transforming treatments for autoimmune and inflammatory diseases, Candid Therapeutics is advancing two lead B-cell depleting TCEs. These therapies utilize innovative biotechnology approaches that not only show promise but also underscore the significance of California’s entrepreneurial spirit. By harnessing the power of T-cell engagers, Candid aims to refine and target treatments more effectively, paving the way for improved patient outcomes.
The biotech landscape in San Diego thrives on innovation and adaptability, traits exemplified by the team’s commitment to groundbreaking research. As Candid pushes the boundaries of medical science, it highlights a broader trend of resilience among California entrepreneurs who are working diligently to develop transformative solutions to today’s pressing health challenges.
Showing Up on a Global Stage
The J.P. Morgan Healthcare Conference is recognized worldwide as a leading event that showcases advancements in the healthcare sector. It draws together thought leaders from across the industry, providing an invaluable networking platform that can foster collaborations and promote investment opportunities. Candid Therapeutics’ participation not only shines a spotlight on its achievements but also enhances San Diego’s reputation as a hub for healthcare innovation.
Key Areas of Focus for Candid Therapeutics
During his presentation, Dr. Song will likely address several critical aspects of Candid’s research and development strategy. The company’s lead T-cell engager platforms are aimed at targeting specific B-cell protein targets, with varying depths of B-cell depletion being explored. This innovative approach represents a new frontier in treating autoimmune diseases and opens up potential pathways for addressing multiple conditions effectively.
Future Perspectives and Community Support
As Candid Therapeutics prepares for its presentation, the company’s progress serves as inspiration for other local startups and small businesses navigating the healthcare landscape. The interconnectedness of the local biotech community, combined with reduced regulatory burdens in California, could further accelerate innovation and economic growth. This landscape exemplifies how supportive local policies and strong entrepreneurial drive can lead to significant advancements beneficial not only to businesses but also to the health and well-being of the broader community.
Conclusion
Candid Therapeutics is poised to make a significant impact at the J.P. Morgan Healthcare Conference, showcasing the resilience and innovation that define San Diego’s entrepreneurial landscape. As local businesses like Candid continue to push the envelope in healthcare, it’s crucial for the community to remain engaged and supportive of these initiatives that contribute to both economic growth and improved health outcomes. Support local businesses and stay attuned to the developments that will shape the future of San Diego’s economy.
Frequently Asked Questions (FAQ)
What is the 44th Annual J.P. Morgan Healthcare Conference?
The 44th Annual J.P. Morgan Healthcare Conference is a prominent event scheduled from January 12 to 15, 2026, in San Francisco, CA. It brings together global industry leaders, emerging companies, and members of the investment community to discuss developments in the healthcare sector.
When is Candid Therapeutics’ presentation at the conference?
Candid Therapeutics’ presentation is scheduled for Wednesday, January 14, 2026, at 7:30 a.m. PT at The Westin St. Francis Hotel in San Francisco.
What will Dr. Ken Song discuss during the presentation?
Dr. Ken Song is expected to discuss Candid’s ongoing clinical progress, particularly advancements in its T-cell engager portfolio.
What is the focus of Candid Therapeutics?
Candid Therapeutics focuses on transforming the treatment of autoimmune and inflammatory diseases through its innovative T-cell engager platforms. The company is advancing two lead B-cell depleting TCEs, aiming to explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets and evaluating various depths of B-cell depletion.
Where is Candid Therapeutics headquartered?
Candid Therapeutics is headquartered in San Diego, CA.
How can I learn more about Candid Therapeutics?
For more information about Candid Therapeutics and their upcoming presentation, please visit their official website.
Key Features of Candid Therapeutics’ Presentation
| Feature | Details |
|---|---|
| Event | 44th Annual J.P. Morgan Healthcare Conference |
| Date and Time | Wednesday, January 14, 2026, at 7:30 a.m. PT |
| Location | The Westin St. Francis Hotel, San Francisco, CA |
| Presenter | Dr. Ken Song, Chairman, President, and CEO of Candid Therapeutics |
| Presentation Focus | Candid’s ongoing clinical progress and advancements in its T-cell engager portfolio |
| Conference Dates | January 12 to 15, 2026 |
| Conference Location | San Francisco, CA |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE SAN DIEGO WRITER
The SAN DIEGO STAFF WRITER represents the experienced team at HERESanDiego.com, your go-to source for actionable local news and information in San Diego, San Diego County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Comic-Con International, San Diego County Fair, and San Diego Pride Festival. Our coverage extends to key organizations like the San Diego Regional Chamber of Commerce and United Way of San Diego County, plus leading businesses in biotechnology, healthcare, and technology that power the local economy such as Qualcomm, Illumina, and Scripps Health. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HEREMissionViejo.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.
